In preparation for large-scale efficacy trials, IPM partners with research centers to determine the HIV incidence (rate of new infections) in their local community.
Conducting microbicide efficacy trials in areas hardest hit by the HIV epidemic not only addresses the needs of the women and communities most at risk for HIV infection, but it also ensures that the clinical trials can deliver faster and more meaningful results for the benefit of many other affected communities.
IPM HIV Incidence Studies Table
|MWHP||Cohort study (1 site)||Tanzania||800 women||Completed|
|ICRH||Cross-sectional study (1 site)||Kenya||800 women||Completed|
|Protocol 002||Protocol 002 (1 site)||Kenya||400 women||Completed|
|IPM 002A||Cross-sectional study (4 sites)||Kenya||
|IPM 002B||Cross-sectional study (1 site)||Nigeria||900 women||Completed|
|HIVINC||Cross-sectional & cohort studies (1 site)||Rwanda||
|IPM 100||Cross-sectional & cohort studies (5 sites)||South Africa||
|IPM 100.1||Cross-sectional & cohort studies (2 sites)||
women (per site)